Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir/rilpivirine

被引：21

作者：

Hill, Lucas A. ^{[1
,2
]}

Abulhosn, Kari K. ^{[1
]}

Yin, Jeffrey F. ^{[1
]}

Bamford, Laura P. ^{[1
]}

机构：

[1] Univ Calif San Diego, San Diego, CA USA

[2] Univ Calif San Diego, 4168 Front St 3rd Floor, San Diego, CA 92103 USA

来源：

AIDS | 2023年 / 37卷 / 04期

关键词：

antiretroviral therapy; cabotegravir; long-acting; resistance; rilpivirine; PLUS RILPIVIRINE; FAILURE;

D O I：

10.1097/QAD.0000000000003446

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Objective:To describe our experience evaluating and initiating individuals on long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) and evaluate factors associated with starting LAI CAB/RPV and reasons for not starting.Design:We conducted a retrospective single-center study at the UC San Diego Owen Clinic.Methods:We included all individuals who expressed interest in treatment with LAI CAB/RPV between April 2021 and June 2022 who had a definitive decision made on starting LAI CAB/RPV.Results:In total, 383 individuals were included with 201 (52.5%) initiating LAI CAB/RPV. Those who initiated LAI CAB/RPV were younger (P = 0.02) and were more likely to be on a two-drug regimen or first-generation integrase inhibitor regimen and less likely to be on a protease inhibitor or multiclass regimen. The most common reasons for not starting LAI CAB/RPV were inconsistent clinic attendance or difficulty being contacted and patient choice not to start. Of those who had a proviral DNA resistance test as workup for LAI CAB/RPV (n = 135), 18.5% had a resistance mutation identified that may have impacted the activity of LAI CAB/RPV.Conclusion:Despite novel challenges over half of our cohort initiated LAI CAB/RPV. Evaluating for potential non-nucleoside reverse transcriptase inhibitor resistance is an important part of the workup for LAI CAB/RPV and proviral DNA resistance testing can be an additional tool to identify potential resistance.

引用

页码：605 / 609

页数：5

共 10 条

[1] Prevalence of genotypic baseline risk factors for cabotegravir plus rilpivirine failure among ARV-naive patients [J].

Charpentier, Charlotte ;

Storto, Alexandre ;

Soulie, Cathia ;

Ferre, Valentine Marie ;

Wirden, Marc ;

Joly, Veronique ;

Lambert-Niclot, Sidonie ;

Palich, Romain ;

Morand-Joubert, Laurence ;

Landman, Roland ;

Lacombe, Karine ;

Katlama, Christine ;

Ghosn, Jade ;

Marcelin, Anne-Genevieve ;

Calvez, Vincent ;

Descamps, Diane .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (11) :2983-2987

[2] Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South [J].

Collins, Lauren F. ;

Corbin-Johnson, Della ;

Asrat, Meron ;

Morton, Zoey P. ;

Dance, Kaylin ;

Condra, Alton ;

Jenkins, Kimberly ;

Todd-Turner, Marie ;

Sumitani, Jeri ;

Smith, Bradley L. ;

Armstrong, Wendy S. ;

Colasanti, Jonathan A. .

OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (09)

[3] Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis [J].

Cutrell, Amy G. ;

Schapiro, Jonathan M. ;

Perno, Carlo F. ;

Kuritzkes, Daniel R. ;

Quercia, Romina ;

Patel, Parul ;

Polli, Joseph W. ;

Dorey, David ;

Wang, Yongwei ;

Wu, Sterling ;

Van Eygen, Veerle ;

Crauwels, Herta ;

Ford, Susan L. ;

Baker, Mark ;

Talarico, Christine L. ;

St Clair, Marty ;

Jeffrey, Jerry ;

White, C. Thomas ;

Vanveggel, Simon ;

Vandermeulen, Kati ;

Margolis, David A. ;

Aboud, Michael ;

Spreen, William R. ;

van Lunzen, Jan .

AIDS, 2021, 35 (09) :1333-1342

[4] Transmitted Drug Resistance in Antiretroviral Therapy-Naive Persons With Acute/Early/Primary HIV Infection: A Systematic Review and Meta-Analysis [J].

Guo, Chunxiang ;

Wu, Yaxin ;

Zhang, Yang ;

Liu, Xinchao ;

Li, Aixin ;

Gao, Meixia ;

Zhang, Tong ;

Wu, Hao ;

Chen, Guanzhi ;

Huang, Xiaojie .

FRONTIERS IN PHARMACOLOGY, 2021, 12

[5] Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort [J].

Machnowska, Patrycja ;

Meixenberger, Karolin ;

Schmidt, Daniel ;

Jessen, Heiko ;

Hillenbrand, Heribert ;

Gunsenheimer-Bartmeyer, Barbara ;

Hamouda, Osamah ;

Kuecherer, Claudia ;

Bannert, Norbert ;

Knechten, H. ;

Panstruga, P. ;

Arasteh, K. ;

Rittweger, M. ;

Schuermann, M. ;

Wesselmann, H. ;

Moll, A. ;

Bohr, U. ;

Jessen, A. B. ;

Schulbin, H. ;

Schmidt, W. ;

Karcher, H. ;

Fischer, K. ;

Schranz, D. ;

Vallee, M. ;

Claus, J. A. ;

Thomas, C. ;

Grimm, R. ;

Klausen, G. ;

Cordes, C. ;

Brockmeyer, N. H. ;

Potthoff, A. ;

Roessler, S. ;

Hower, M. ;

Bachmann, C. ;

Spornraft-Ragaller, P. ;

Teichmann, D. ;

Haeussinger, D. ;

Jensen, B. ;

Arbter, P. A. ;

Haars, U. ;

Esser, S. ;

Schenk-Westkamp, P. ;

Usadel, S. ;

Mueller, M. C. ;

Kreft, B. ;

Lange, D. ;

Polywka, S. ;

Degen, O. ;

Plettenbger, A. ;

Kuhlendahl, F. .

PLOS ONE, 2019, 14 (01)

[6] Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study [J].

Overton, Edgar T. ;

Richmond, Gary ;

Rizzardini, Giuliano ;

Jaeger, Hans ;

Orrell, Catherine ;

Nagimova, Firaya ;

Bredeek, Fritz ;

Deltoro, Miguel Garcia ;

Swindells, Susan ;

Andrade-Villanueva, Jaime Federico ;

Wong, Alexander ;

Khuong-Josses, Marie-Aude ;

Van Solingen-Ristea, Rodica ;

van Eygen, Veerle ;

Crauwels, Herta ;

Ford, Susan ;

Talarico, Christine ;

Benn, Paul ;

Wang, Yuanyuan ;

Hudson, Krischan J. ;

Chounta, Vasiliki ;

Cutrell, Amy ;

Patel, Parul ;

Shaefer, Mark ;

Margolis, David A. ;

Smith, Kimberly Y. ;

Vanveggel, Simon ;

Spreen, William .

LANCET, 2020, 396 (10267) :1994-2005

[7] Human immunodeficiency virus reverse transcriptase and protease sequence database [J].

Rhee, SY ;

Gonzales, MJ ;

Kantor, R ;

Betts, BJ ;

Ravela, J ;

Shafer, RW .

NUCLEIC ACIDS RESEARCH, 2003, 31 (01) :298-303

[8] Long-Acting Injectable Cabotegravir plus Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials [J].

Rizzardini, Giuliano ;

Overton, Edgar T. ;

Orkin, Chloe ;

Swindells, Susan ;

Arasteh, Keikawus ;

Gorgolas Hernandez-Mora, Miguel ;

Pokrovsky, Vadim ;

Girard, Pierre-Marie ;

Oka, Shinichi ;

Andrade-Villanueva, Jaime F. ;

Richmond, Gary J. ;

Baumgarten, Axel ;

Masia, Mar ;

Latiff, Gulam ;

Griffith, Sandy ;

Harrington, Conn M. ;

Hudson, Krischan J. ;

St Clair, Marty ;

Talarico, Christine L. ;

Patel, Parul ;

Cutrell, Amy ;

Van Eygen, Veerle ;

D'Amico, Ronald ;

Mrus, Joseph M. ;

Wu, Sterling ;

Ford, Susan L. ;

Chow, Ken ;

Roberts, Jeremy ;

Wills, Angela ;

Walters, Nicola ;

Vanveggel, Simon ;

Van Solingen-Ristea, Rodica ;

Crauwels, Herta ;

Smith, Kimberly Y. ;

Spreen, William R. ;

Margolis, David A. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (04) :498-506

[9] Rationale and uses of a public HIV drug-resistance database [J].

Shafer, Robert W. .

JOURNAL OF INFECTIOUS DISEASES, 2006, 194 :S51-S58

[10]

ViiV Healthcare, 2022, CAB PACK INS

← 1 →